Extract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a devastating complication that occurs in about 3% of survivors of acute pulmonary embolism (PE) [1]. Genetic risk factors may differentiate patients with acute PE who develop CTEPH from those who do not develop CTEPH. The Factor V Leiden (FVL) and Prothrombin G20210A (PT) variants are the most common genetic risk factors for venous thromboembolism (VTE) [2, 3]. In European CTEPH patients, the frequencies of these variants are not increased compared with either patients with non-CTEPH pulmonary hypertension or healthy controls [4–7]. While these data suggest that genetic risk factors for CTEPH and PE may be distinct [8], no studies have directly compared the frequencies of these variants in patients with CTEPH and patients with acute PE who did not develop CTEPH.
Abstract
The Factor V Leiden variant is identified significantly less frequently among CTEPH patients who had their first venous thromboembolism prior to 50 years of age than among similar patients with acute pulmonary embolism who did not develop CTEPH https://bit.ly/2W6qoLK
Acknowledgements
The authors wish to thank Scott Stevens and Scott Woller (Dept of Medicine, Intermountain Medical Center, Murray, Utah) for help in enrolling PE patients in the thrombosis clinic at Intermountain Medical Center.
Footnotes
Conflict of interest: K. Sumner has nothing to disclose.
Conflict of interest: J. Carlsen has nothing to disclose.
Conflict of interest: M.M. Cirulis has nothing to disclose.
Conflict of interest: E.L. Wilson has nothing to disclose.
Conflict of interest: A. Gadre has nothing to disclose.
Conflict of interest: T.M. Fernandes reports personal fees from Bayer and Bristol-Meyers-Squibb, outside the submitted work.
Conflict of interest: L.M. Brown has nothing to disclose.
Conflict of interest: D.H. Best has nothing to disclose.
Conflict of interest: C.G. Elliott grants from Arena Pharmaceuticals, Respira Therapeutics and Lung Biotechnology PBC, and has acted as study PI for United Therapeutics and committee chair for Lung Rx LLC, outside the submitted work.
Conflict of interest: M.W. Dodson reports grants from Actelion Pharmaceuticals (via the Entelligence Young Investigator Program) and Intermountain Research and Medical Foundation, during the conduct of the study.
Support statement: This research was supported by a grant from Actelion Pharmaceuticals US, Inc. through the Actelion Entelligence Young Investigator Program. This work was also supported by a grant from the Intermountain Research and Medical Foundation. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received January 8, 2020.
- Accepted April 26, 2020.
- Copyright ©ERS 2020